Achieve Life Sciences, Inc. (ACHV) – What Are Analysts Thinking About This Stock?

Achieve Life Sciences, Inc. (NASDAQ:ACHV) has earned a consensus recommendation of “Buy” from the nine brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $15.50.

Several analysts have issued reports on the company. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Achieve Life Sciences in a report on Wednesday, August 12th. Stifel Nicolaus set a $18.00 target price on shares of Achieve Life Sciences and gave the stock a “buy” rating in a report on Tuesday, September 29th. UBS Group reissued a “buy” rating on shares of Achieve Life Sciences in a research report on Wednesday, August 12th. Wall Street Zen downgraded shares of Achieve Life Sciences from a “hold” rating to a “strong sell” rating in a research report on Saturday, August 15th. Finally, Morgan Stanley began coverage on shares of Achieve Life Sciences in a report on Thursday, August 13th. They set an “overweight” rating and a $13.00 price target on the stock.

Insider Buying and Selling

In other Achieve Life Sciences news, Director Richard Stewart sold 20,626 shares of Achieve Life Sciences stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $8.49, for a total transaction of $175,114.74. Following the transaction, the director directly owned 208,249 shares in the company, valued at approximately $1,768,034.01. The trade was a 9.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.80% of the company’s stock.

Institutional Trading of Achieve Life Sciences

A number of hedge funds have recently modified their holdings of the business. SLT Holdings LLC purchased a new position in shares of Achieve Life Sciences during the third quarter valued at $89,000. WINTON GROUP Ltd purchased a new stake in Achieve Life Sciences in the 2nd quarter worth about $278,000. Frazier Life Sciences Management L.P. purchased a new stake in Achieve Life Sciences in the 2nd quarter worth about $49,725,000. AXQ Capital LP lifted its stake in Achieve Life Sciences by 65.6% in the 2nd quarter. AXQ Capital LP now owns 25,173 shares of the biopharmaceutical company’s stock worth $164,000 after acquiring an additional 9,972 shares in the last quarter. Finally, Alyeska Investment Group L.P. purchased a new stake in Achieve Life Sciences in the 2nd quarter worth about $12,575,000. Hedge funds and other institutional investors own 33.52% of the company’s stock.

Achieve Life Sciences Stock Performance

NASDAQ:ACHV opened at $6.50 on Friday. The company has a 50-day moving average of $7.59 and a 200-day moving average of $6.15. The firm has a market cap of $668.85 million, a price-to-earnings ratio of -4.19 and a beta of 2.30. The company has a current ratio of 0.95, a quick ratio of 0.95 and a debt-to-equity ratio of 0.87. Achieve Life Sciences has a twelve month low of $2.62 and a twelve month high of $8.64.

Achieve Life Sciences (NASDAQ:ACHV) last released its earnings results on Tuesday, August 11th. The biopharmaceutical company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.64). Analysts forecast that Achieve Life Sciences will post -0.92 earnings per share for the current fiscal year.

About Achieve Life Sciences

Achieve Life Sciences, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cytisinicline, a therapy designed to help adults quit smoking and overcome nicotine addiction. Cytisinicline is an oral, plant-based small molecule that partially activates nicotinic acetylcholine receptors, with the goal of reducing nicotine cravings and withdrawal symptoms.

The company has evaluated cytisinicline in clinical studies involving adults who smoke cigarettes, including trials assessing smoking cessation and cessation of electronic cigarette use.